Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination

Raquel Ciérvide; Angel Montero Luis; Eduardo García-Rico; Mariola Garcia-Aranda; Mercedes Herrero; Jessica Skaarup; Leticia Benasi; Maria Jose Barrera; Estela Vega; Beatriz Rojas; Raquel Bratos; Ana Luna; Manuela Parras; Maria Lopez; Ana Delgado; Paloma Quevedo; Silvia Castilla; Margarita Feyjoo; Ana Higueras; Mario Prieto; Ana Suarez-Gauthier; Lina Garcia-Cañamaque; Nieves Escolán; Beatriz Alvarez; Xin Chen; Rosa Alonso; Mercedes Lopez; Ovidio Hernando; Jeannette Valero; Emilio Sánchez Sahugar; Eva Ciruelos; Carmen Rubio

doi:10.20944/preprints202208.0488.v1

A peer-reviewed article of this Preprint also exists.

Ciérvide, R.; Montero, Á.; García-Rico, E.; García-Aranda, M.; Herrero, M.; Skaarup, J.; Benassi, L.; Barrera, M.J.; Vega, E.; Rojas, B.; Bratos, R.; Luna, A.; Parras, M.; López, M.; Delgado, A.; Quevedo, P.; Castilla, S.; Feyjoo, M.; Higueras, A.; Prieto, M.; Suarez-Gauthier, A.; Garcia-Cañamaque, L.; Escolán, N.; Álvarez, B.; Chen, X.; Alonso, R.; López, M.; Hernando, O.; Valero, J.; Sánchez, E.; Ciruelos, E.; Rubio, C. Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination. Cancers 2022, 14, 4531. Ciérvide, R.; Montero, Á.; García-Rico, E.; García-Aranda, M.; Herrero, M.; Skaarup, J.; Benassi, L.; Barrera, M.J.; Vega, E.; Rojas, B.; Bratos, R.; Luna, A.; Parras, M.; López, M.; Delgado, A.; Quevedo, P.; Castilla, S.; Feyjoo, M.; Higueras, A.; Prieto, M.; Suarez-Gauthier, A.; Garcia-Cañamaque, L.; Escolán, N.; Álvarez, B.; Chen, X.; Alonso, R.; López, M.; Hernando, O.; Valero, J.; Sánchez, E.; Ciruelos, E.; Rubio, C. Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination. Cancers 2022, 14, 4531.

Abstract

Primary systemic treatment (PST) downsizes the tumor and improves pathological response. The aim of this study is to analyze the feasibility and tolerance of primary concurrent radio-chemotherapy (PCRT) in breast cancer patients. Patients with localized TN/HER2+ tumors were enrolled in this prospective study. Radiation is delivered concomitantly during the first 3 weeks of chemotherapy, and it is based on a 15 fractions scheme (40.5Gy/2.7Gy per fraction to whole breast and nodal levels I-IV. Chemotherapy is based on Pertuzumab-Trastuzumab-Paclitaxel followed by anthracyclines in HER2+ and CBDCA-Paclitaxel followed by anthracyclines in TN breast cancers patients. 58 patients were enrolled, 25 patients (43%) were TN and 33 patients HER2+ (57%). With a median follow-up of 24.2 months, 56 patients completed PCRT and surgery. A total of 35 patients (87.5%) achieved >90% loss of invasive carcinoma cell in the surgical specimen. The 70.8% and the 53.1% of patients with TN and HER-2+ subtype respectively achieved complete pathological response (pCR). This is the first study of concurrent neoadjuvant treatment in breast cancer in which three strategies are applied simultaneously: fractionation of RT in 15 sessions, adjustment of CT to tumor phenotype and local planning by PET. The pCR rates are encouraging.

Keywords

Subject

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Not displayed online.

Please leave your comment to this article below.

Mathematical equations can be typed in either LaTeX formats \\[ ... \\] or $$ ... $$, or MathML format <math> ... </math>. Try the LaTeX or MathML example.

Type equation:

Preview:

Copy equation into message below

Close menu

Please click a symbol to insert it into the message box below:

Please enter the link here:

Optionally, you can enter text that should appear as linked text:

Copy link into message below

Please enter or paste the URL to the image here (please only use links to jpg/jpeg, png and gif images):

Copy image into message below

Type author name or keywords to filter the list of references in this group (you can add a new citation under Bibliography):

No existing citations in Discussion Group

Wikify editor is a simple editor for wiki-style mark-up. It was written by MDPI for Sciforum in 2014. The rendering of the mark-up is based on Wiky.php with some tweaks. Rendering of mathematical equations is done with MathJax. Please send us a message for support or for reporting bugs.

Please declare any conflicts of interest you may have with this paper, financial or otherwise.

I do not have a conflict of interest

I would like to declare a conflict of interest

Display my name on the website

Captcha

Renew

I accept the following conditions:

Comments must follow the standards of professional discourse and should focus on the scientific content of the article. Insulting or offensive language, personal attacks and off-topic remarks will not be permitted. Comments must be written in English. Preprints reserves the right to remove comments without notice. Readers who post comments are obliged to declare any competing interests, financial or otherwise.

Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination

Abstract

Keywords

Subject

Comments (0)